Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has licensed computational technology from San Diego-based Eidogen-Sertanty to aid it in its drug discovery programs.
Subscribe to our email newsletter
Under the agreement, scientists at AstraZeneca R&D will access Eidogen-Sertanty’s target informatics platform (TIP) and EVE comparative visualization software to assist drug discovery efforts within their cancer and anti-infective therapeutic programs. The financial terms of the deal were not disclosed.
TIP is a protein structure informatics system that integrates protein structural data and ligand binding site analysis.
“We are very excited that AstraZeneca R&D Boston has selected TIP to assist their drug discovery efforts,” said Dr Steve Muskal, CEO of Eidogen-Sertanty. “We’re confident that TIP will help AstraZeneca scientists accelerate lead discovery programs across a wide variety of target families and therapeutic areas.”
Anglo-Swedish company AstraZeneca is engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services.